Arch Biopartners Inc. (ACHFF)
- Previous Close
1.3500 - Open
1.3400 - Bid 1.3200 x 40000
- Ask 1.3300 x 40000
- Day's Range
1.3400 - 1.3600 - 52 Week Range
0.7200 - 1.8800 - Volume
1,100 - Avg. Volume
7,745 - Market Cap (intraday)
87.717M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date Aug 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.
www.archbiopartners.comRecent News: ACHFF
View More
Performance Overview: ACHFF
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACHFF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACHFF
View MoreValuation Measures
Market Cap
87.77M
Enterprise Value
91.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-185.89%
Return on Assets (ttm)
-81.20%
Return on Equity (ttm)
--
Revenue (ttm)
1.38M
Net Income Avi to Common (ttm)
-2.57M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
43.95k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.5M
Research Analysis: ACHFF
View MoreCompany Insights: ACHFF
ACHFF does not have Company Insights